Cargando…

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension

The efficacy and safety of azilsartan medoxomil (AZL‐M) were evaluated in African‐American patients with hypertension in a 6‐week, double‐blind, randomized, placebo‐controlled trial, for which the primary end point was change from baseline in 24‐hour mean systolic blood pressure (BP). There were 413...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Wallace, White, William B., Sica, Domenic, Bakris, George L., Weber, Michael A., Handley, Alison, Perez, Alfonso, Cao, Charlie, Kupfer, Stuart, Saunders, Elijah B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Hypertension Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031359/ https://www.ncbi.nlm.nih.gov/pubmed/28493376 http://dx.doi.org/10.1111/jch.12993

Ejemplares similares

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
por: Bönner, G, et al.
Publicado: (2013)

Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension
por: Weber, Michael A., et al.
Publicado: (2014)

A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension
por: Cushman, William C., et al.
Publicado: (2018)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
por: Juhasz, Attila, et al.
Publicado: (2018)

Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes
por: White, William B., et al.
Publicado: (2016)

A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone
por: Weber, Michael A, et al.
Publicado: (2018)

Safety, Tolerability, and Efficacy of Azilsartan Medoxomil With or Without Chlorthalidone During and After 8 Months of Treatment for Hypertension
por: Kipnes, Mark S., et al.
Publicado: (2015)

A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment
por: Ayyagari, Rajeev, et al.
Publicado: (2018)

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
por: Bramlage, Peter, et al.
Publicado: (2015)

Single‐Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment
por: Dudkowski, Caroline, et al.
Publicado: (2017)

Is the newest angiotensin‐receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta‐analysis
por: Wang, Ji‐Guang, et al.
Publicado: (2021)

Spectrophotometric and Spectrofluorimetric Studies on Azilsartan Medoxomil and Chlorthalidone to Be Utilized in Their Determination in Pharmaceuticals
por: Ebeid, Walid M, et al.
Publicado: (2014)

Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study
por: Handley, Alison, et al.
Publicado: (2016)

Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis
por: Kumar, Lakshya, et al.
Publicado: (2023)

New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
por: Volpe, Massimo, et al.
Publicado: (2012)

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy
por: Angeloni, Emiliano
Publicado: (2016)

Angiotensin receptor blockers (ARBs) in hypertension patients: earlier use of these bettertolerated medications is warranted
por: Aalbers, J
Publicado: (2010)

Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults
por: Webb, Nicholas J. A., et al.
Publicado: (2016)

Use of azilsartan medoxomil in the primary-care setting in Germany: A real-world evidence study
por: Ehlken, Birgit, et al.
Publicado: (2019)

Efficacy and Safety of Azilsartan Medoxomil and Telmisartan in Hypertensive Patients: A Randomized, Assessor-Blinded Study
por: Garg, Megha, et al.
Publicado: (2020)

Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy Subjects
por: Harrell, Robert E., et al.
Publicado: (2015)

Effects of Food Intake on the Pharmacokinetics of Azilsartan Medoxomil and Chlorthalidone Alone and in Fixed‐Dose Combination in Healthy Adults
por: Dudkowski, Caroline, et al.
Publicado: (2016)

A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia
por: Deerochanawong, Chaicharn, et al.
Publicado: (2022)

Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice
por: Zhu, Ye, et al.
Publicado: (2019)

Association of uncontrolled blood pressure in apparent treatment‐resistant hypertension with increased risk of major adverse cardiovascular events plus
por: Bakris, George, et al.
Publicado: (2023)

Efficacy and safety of different doses of azilsartan medoxomil in patients with hypertension: A protocol of a network meta-analysis
por: Zhang, Yan, et al.
Publicado: (2019)

The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers
por: Fukuda, Michio, et al.
Publicado: (2019)

The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg
por: Schrader, J, et al.
Publicado: (2009)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

Endothelial Factors and Diabetic Nephropathy
por: Karalliedde, Janaka, et al.
Publicado: (2011)

Benefits of Tight Blood Pressure Control in Diabetic Patients With Hypertension: Importance of early and sustained implementation of effective treatment strategies
por: Parati, Gianfranco, et al.
Publicado: (2011)

Antihypertensive Treatment and Blood Pressure in Diabetic and Nondiabetic Patients: The lower, the better?
por: Mancia, Giuseppe, et al.
Publicado: (2011)

Blood Pressure: The Lower, the Better: The con side
por: Grossman, Ehud
Publicado: (2011)

Diuretic Treatment of Hypertension
por: Grossman, Ehud, et al.
Publicado: (2011)

RAS Blockade for Every Diabetic Patient: Pro and Con
por: Ruilope, Luis M., et al.
Publicado: (2011)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Limitations and Future Treatment Options in Type 2 Diabetes With Renal Impairment
por: Ritz, Eberhard
Publicado: (2011)

Individualization of Antihypertensive Drug Treatment
por: Mancia, Giuseppe, et al.
Publicado: (2013)

Intolerance to Statins: Mechanisms and Management
por: Bitzur, Rafael, et al.
Publicado: (2013)

Prognostic Value of Blood Pressure Variability and Average Blood Pressure Levels in Patients With Hypertension and Diabetes
por: Parati, Gianfranco, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_40q0poogj0cta9eghsgfhctc77